Filtros de búsqueda

Lista de obras de Fortunato Ciardiello

30 Immunotherapy in advanced NSCLC—from the ‘tsunami’ of therapeutic knowledge to a clinical practice algorithm: results from an international expert panel meeting of the Italian Association of Thoracic Oncology (AIOT).

artículo científico publicado en 2018

A Preliminary Study for Quantitative Assessment with HFUS (High- Frequency Ultrasound) of Nodular Skin Melanoma Breslow Thickness in Adults Before Surgery: Interdisciplinary Team Experience

artículo científico publicado en 2020

A Randomized Phase II Study of Sorafenib/Gemcitabine or Sorafenib/Erlotinib for Advanced Non–Small-Cell Lung Cancer in Elderly Patients or Patients with a Performance Status of 2: Treatment Rationale and Protocol Dynamics

artículo científico publicado en 2007

A meta-analysis on the interaction between HER-2 expression and response to endocrine treatment in advanced breast cancer

artículo científico publicado en 2005

A multicenter phase II study of induction chemotherapy with FOLFOX-4 and cetuximab followed by radiation and cetuximab in locally advanced oesophageal cancer.

artículo científico publicado en 2011

A multicenter, open-label phase II study of metformin with erlotinib in second-line therapy of stage IV non-small-cell lung cancer patients: treatment rationale and protocol dynamics of the METAL trial.

artículo científico publicado en 2014

A novel MDM2 anti-sense oligonucleotide has anti-tumor activity and potentiates cytotoxic drugs acting by different mechanisms in human colon cancer.

artículo científico publicado en 2000

A phase II study of biweekly oxaliplatin plus infusional 5-fluorouracil and folinic acid (FOLFOX-4) as first-line treatment of advanced gastric cancer patients

artículo científico publicado en 2005

A possible connective tissue primary lymphoepithelioma-like carcinoma (LELC).

artículo científico publicado en 2010

A randomized phase II study of pemetrexed or RAD001 as second-line treatment of advanced non-small-cell lung cancer in elderly patients: treatment rationale and protocol dynamics.

artículo científico publicado en 2007

ALK inhibitors and advanced non-small cell lung cancer (review).

artículo científico

ALK inhibitors in the treatment of advanced NSCLC.

artículo científico

ALK inhibitors: a new targeted therapy in the treatment of advanced NSCLC.

artículo científico publicado en 2013

Adaptation of international guidelines for metastatic colorectal cancer: an asian consensus

artículo científico publicado en 2014

Addition of cetuximab to chemotherapy as first-line treatment for KRAS wild-type metastatic colorectal cancer: pooled analysis of the CRYSTAL and OPUS randomised clinical trials

artículo científico publicado en 2012

Adjuvant chemoradiotherapy in patients with stage III or IV radically resected gastric cancer: a pilot study.

artículo científico publicado en 2010

Adjuvant chemotherapy with epirubicin, leucovorin, 5-fluorouracil and etoposide regimen in resected gastric cancer patients: a randomized phase III trial by the Gruppo Oncologico Italia Meridionale (GOIM 9602 Study)

artículo científico publicado en 2007

An international, multicenter, randomized phase III study of first-line erlotinib followed by second-line cisplatin/gemcitabine versus first-line cisplatin/gemcitabine followed by second-line erlotinib in advanced non-small-cell lung cancer: treatme

artículo científico publicado en 2008

Angiogenesis: a target for cancer therapy

artículo científico publicado en 2004

Anti PD-1 and PDL-1 Immunotherapy in the Treatment of Advanced Non- Small Cell Lung Cancer (NSCLC): A Review on Toxicity Profile and its Management

artículo científico

Anti-epidermal growth factor receptor drugs in cancer therapy

artículo científico publicado en 2002

Anti-epidermal growth factor receptor monoclonal antibodies in cancer therapy.

artículo científico publicado en 2009

Anti-sense oligonucleotides directed against EGF-related growth factors enhance anti-proliferative effect of conventional anti-tumor drugs in human colon-cancer cells

artículo científico publicado en 1997

Anti-tumor activity of the combination of cetuximab, an anti-EGFR blocking monoclonal antibody and ZD6474, an inhibitor of VEGFR and EGFR tyrosine kinases

artículo científico publicado en 2006

Antiangiogenic drugs in non-small cell lung cancer treatment.

artículo científico publicado en 2006

Antisense oligonucleotides targeting the epidermal growth factor receptor inhibit proliferation, induce apoptosis, and cooperate with cytotoxic drugs in human cancer cell lines.

artículo científico publicado en 2001

Antisense strategies targeting protein kinase C: preclinical and clinical development.

artículo científico publicado en 2003

Antisense targeting protein kinase A type I as a drug for integrated strategies of cancer therapy.

artículo científico publicado en 2003

Antitumor activity of ZD6126, a novel vascular-targeting agent, is enhanced when combined with ZD1839, an epidermal growth factor receptor tyrosine kinase inhibitor, and potentiates the effects of radiation in a human non-small cell lung cancer xeno

artículo científico publicado en 2004

Antitumor activity of ZD6474, a vascular endothelial growth factor receptor tyrosine kinase inhibitor, in human cancer cells with acquired resistance to antiepidermal growth factor receptor therapy.

artículo científico publicado en 2004

Antitumor activity of ZD6474, a vascular endothelial growth factor-2 and epidermal growth factor receptor small molecule tyrosine kinase inhibitor, in combination with SC-236, a cyclooxygenase-2 inhibitor.

artículo científico publicado en 2005

Antitumor activity of bortezomib in human cancer cells with acquired resistance to anti-epidermal growth factor receptor tyrosine kinase inhibitors

artículo científico publicado en 2011

Antitumor activity of pimasertib, a selective MEK 1/2 inhibitor, in combination with PI3K/mTOR inhibitors or with multi-targeted kinase inhibitors in pimasertib-resistant human lung and colorectal cancer cells

artículo científico publicado en 2013

Antitumor activity of sorafenib in human cancer cell lines with acquired resistance to EGFR and VEGFR tyrosine kinase inhibitors

artículo científico publicado en 2011

Antitumor effects of ZD6474, a small molecule vascular endothelial growth factor receptor tyrosine kinase inhibitor, with additional activity against epidermal growth factor receptor tyrosine kinase.

artículo científico publicado en 2003

Antitumor efficacy of Kisspeptin in human malignant mesothelioma cells.

artículo científico publicado en 2018

Antitumour efficacy of MEK inhibitors in human lung cancer cells and their derivatives with acquired resistance to different tyrosine kinase inhibitors

artículo científico publicado en 2011

Applying the ESMO-Magnitude of Clinical Benefit Scale in real life.

artículo científico publicado en 2016

Assessment of a HER2 scoring system for colorectal cancer: results from a validation study

artículo científico

Awareness, Understanding, and Adoption of Precision Medicine to Deliver Personalized Treatment for Patients With Cancer: A Multinational Survey Comparison of Physicians and Patients

artículo científico publicado en 2016

BEVERLY: Rationale and Design of a Randomized Open-Label Phase III Trial Comparing Bevacizumab Plus Erlotinib Versus Erlotinib Alone as First-Line Treatment of Patients With EGFR-Mutated Advanced Nonsquamous Non-Small-Cell Lung Cancer

artículo científico publicado en 2016

Beyond bevacizumab: new anti-VEGF strategies in colorectal cancer

artículo científico publicado en 2012

Biomarker analysis of the phase 3 TORCH trial for first line erlotinib versus chemotherapy in advanced non-small cell lung cancer patients

artículo científico publicado en 2017

Biosimilars: a position paper of the European Society for Medical Oncology, with particular reference to oncology prescribers.

artículo científico publicado en 2016

Brexit: a European perspective.

artículo científico publicado en 2016

CRIPTO-1: a novel target for therapeutic intervention in human carcinoma

artículo científico publicado en 2004

Cancer diagnosis in patients with heart failure: epidemiology, clinical implications and gaps in knowledge

artículo científico publicado en 2018

Cancer resistance to therapies against the EGFR-RAS-RAF pathway: The role of MEK.

artículo científico publicado en 2016

Capecitabine plus weekly oxaliplatin in gastrointestinal tumors: a phase I study.

artículo científico publicado en 2006

Cetuximab administered once every second week to patients with metastatic colorectal cancer: a two-part pharmacokinetic/pharmacodynamic phase I dose-escalation study.

artículo científico publicado en 2009

Cetuximab and gemcitabine in elderly or adult PS2 patients with advanced non-small-cell lung cancer: The cetuximab in advanced lung cancer (CALC1-E and CALC1-PS2) randomized phase II trials.

artículo científico publicado en 2010

Cetuximab in advanced non-small cell lung cancer (NSCLC): the showdown?

artículo científico publicado en 2014

Cetuximab in the treatment of colorectal cancer.

artículo científico publicado en 2005

Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status

artículo científico publicado en 2011

Cetuximab, A Chimeric Anti-Epidermal Growth Factor Receptor Monoclonal Antibody, in Colorectal Cancer Treatment

Cetuximab, a chimeric human mouse anti-epidermal growth factor receptor monoclonal antibody, in the treatment of human colorectal cancer.

artículo científico publicado en 2007

Chemoradiotherapy as adjuvant treatment of gastric cancer.

artículo científico publicado en 2007

Chemosensitization by antisense oligonucleotides targeting MDM2.

artículo científico publicado en 2005

Chronic inflammation and oxidative stress in human carcinogenesis

artículo científico publicado en 2007

Clinical activity of FOLFIRI plus cetuximab according to extended gene mutation status by next-generation sequencing: findings from the CAPRI-GOIM trial.

artículo científico publicado en 2014

Clinical management of advanced gastric cancer: the role of new molecular drugs.

artículo científico

Clinico-Pathologic and Biologic Predictors of EGFR Inhibitors Activity and Efficacy in Lung and in Colorectal Cancer

Combination of Anti-EGFR Drugs and Other Molecular Targeted Agents as Anti-Cancer Strategy

Combination of a selective cyclooxygenase-2 inhibitor with epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 and protein kinase A antisense causes cooperative antitumor and antiangiogenic effect.

artículo científico publicado en 2003

Combination of epidermal growth factor receptor inhibitors and antiangiogenic drugs: a model for treatment

Combination of standard chemotherapy and targeted agents

artículo científico publicado en 2007

Combined targeted inhibition of bcl-2, bcl-XL, epidermal growth factor receptor, and protein kinase A type I causes potent antitumor, apoptotic, and antiangiogenic activity.

artículo científico publicado en 2003

Combined targeted therapies in non-small cell lung cancer: a winner strategy?

artículo científico publicado en 2007

Combined targeting of EGFR-dependent and VEGF-dependent pathways: rationale, preclinical studies and clinical applications

scientific article published on July 2008

Combined targeting of epidermal growth factor receptor and MDM2 by gefitinib and antisense MDM2 cooperatively inhibit hormone-independent prostate cancer

artículo científico publicado en 2004

Combining targeted therapies and drugs with multiple targets in the treatment of NSCLC.

artículo científico publicado en 2006

Comment on 'a comparison of three methods for detecting KRAS mutations in formalin-fixed colorectal cancer specimens'

artículo científico publicado en 2012

Comparative Study of NGS Platform Ion Torrent Personal Genome Machine and Therascreen Rotor-Gene Q for the Detection of Somatic Variants in Cancer

artículo científico publicado en 2020

Complete response to capecitabine in a frail, elderly patient with metastatic colorectal cancer: A case report

artículo científico publicado en 2016

Complete response to preoperative chemoradiation and survival in esophageal cancer: a pooled analysis of three single-institution phase II trials.

artículo científico publicado en 2011

Consensus statement. Workshop on therapeutic resistance in breast cancer: impact of growth factor signalling pathways and implications for future treatment.

artículo científico publicado en 2005

Conversion chemotherapy followed by hepatic resection in colorectal cancer with initially unresectable liver-limited metastases

artículo científico publicado en 2013

Cooperative antitumor effect of multitargeted kinase inhibitor ZD6474 and ionizing radiation in glioblastoma

artículo científico publicado en 2005

Cooperative inhibitory effect of ZD1839 (Iressa) in combination with trastuzumab (Herceptin) on human breast cancer cell growth.

artículo científico publicado en 2002

Correlation between efficacy and skin rash occurrence following treatment with the epidermal growth factor receptor inhibitor cetuximab: a single institution retrospective analysis.

artículo científico publicado en 2009

Cripto enhances the tyrosine phosphorylation of Shc and activates mitogen-activated protein kinase (MAPK) in mammary epithelial cells

artículo científico publicado en 1997

Critical appraisal of the use of regorafenib in the management of colorectal cancer.

artículo científico publicado en 2013

Current status of targeted therapies in advanced gastric cancer.

artículo científico

Delivering precision medicine in oncology today and in future-the promise and challenges of personalised cancer medicine: a position paper by the European Society for Medical Oncology (ESMO).

artículo científico publicado en 2014

Delivery optimization of erlotinib according to toxicity: may clinical practice go beyond research?

artículo científico publicado en 2013

Detection of KRAS mutations in colorectal carcinoma patients with an integrated PCR/sequencing and real-time PCR approach.

artículo científico publicado en 2010

Detection of erbB2 copy number variations in plasma of patients with esophageal carcinoma

artículo científico publicado en 2011

Determination of molecular marker expression can predict clinical outcome in colon carcinomas.

artículo científico publicado en 2004

Differential immunohistochemical detection of transforming growth factor α, amphiregulin and CRIPTO in human normal and malignant breast tissues

article

Down-regulation of type I protein kinase A by transfection of human breast cancer cells with an epidermal growth factor receptor antisense expression vector

scientific article published on 01 January 1998

Dual MET and SMO Negative Modulators Overcome Resistance to EGFR Inhibitors in Human Nonsmall Cell Lung Cancer

artículo científico publicado en 2017

EGF-related peptides are involved in the proliferation and survival of MDA-MB-468 human breast carcinoma cells

artículo científico publicado en 1999

EGFR FISH assay predicts for response to cetuximab in chemotherapy refractory colorectal cancer patients

artículo científico publicado en 2007

EGFR antagonists in cancer treatment

artículo científico publicado en 2008

EGFR in Tumor-Associated Myeloid Cells Promotes Development of Colorectal Cancer in Mice and Associates With Outcomes of Patients

artículo científico publicado en 2017

EGFR-targeted therapy

artículo científico

ESMO Consensus Guidelines for management of patients with colon and rectal cancer. A personalized approach to clinical decision making

artículo científico publicado en 2012

ESMO and WHO: 14 years of working in partnership on cancer control.

artículo científico publicado en 2016

Editorial [ The Role of Epidermal Growth Factor Receptor (EGFR) Targeting Drugs in the Treatment of Cancer Guest Editor: Fortunato Ciardiello ]

Effect of cetuximab in recurrent and refractory squamous cell carcinoma of the head and neck (SCCHN): a case report

Effect of preoperative chemoradiotherapy on outcome of patients with locally advanced esophagogastric junction adenocarcinoma-a pilot study

artículo científico publicado en 2014

Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis

artículo científico publicado en 2010

Elevated perioperative serum vascular endothelial growth factor levels in patients with colon carcinoma

artículo científico publicado en 2004

Emerging VEGF-receptor inhibitors for colorectal cancer

artículo científico

Emerging drugs targeting PD-1 and PD-L1: reality or hope?

artículo científico

Emerging mitotic inhibitors for non-small cell carcinoma

artículo científico

Enhancement of antitumor activity of ionizing radiation by combined treatment with the selective epidermal growth factor receptor-tyrosine kinase inhibitor ZD1839 (Iressa).

artículo científico publicado en 2002

Epidermal growth factor receptor (EGFR) as a target in cancer therapy: understanding the role of receptor expression and other molecular determinants that could influence the response to anti-EGFR drugs.

artículo científico publicado en 2003

Epidermal growth factor receptor (EGFR) inhibitors in cancer therapy.

artículo científico publicado en 2005

Epidermal growth factor receptor inhibitors in cancer treatment.

artículo científico publicado en 2005

Epidermal growth factor receptor inhibitors in non-small-cell lung cancer

artículo científico

Epidermal growth factor receptor tyrosine kinase inhibitors in late stage clinical trials.

artículo científico publicado en 2003

Epidermal growth factor-related peptides and their receptors in human malignancies

artículo científico publicado en 1995

Epidermal growth factor-related peptides in the pathogenesis of human breast cancer.

artículo científico publicado en 1994

Eribulin for metastatic breast cancer (MBC) treatment: a retrospective, multicenter study based in Campania, south Italy (Eri-001 trial).

artículo científico publicado en 2017

Erlotinib in cancer treatment.

artículo científico publicado en 2007

Erlotinib in non-small cell lung cancer treatment: current status and future development

artículo científico publicado en 2007

Erlotinib: an EGF receptor tyrosine kinase inhibitor in non-small-cell lung cancer treatment

artículo científico publicado en 2008

Exemestane and Everolimus combination treatment of hormone receptor positive, HER2 negative metastatic breast cancer: A retrospective study of 9 cancer centers in the Campania Region (Southern Italy) focused on activity, efficacy and safety.

artículo científico publicado en 2018

Expression of epidermal growth factor receptor correlates with disease relapse and progression to androgen-independence in human prostate cancer

artículo científico publicado en 2002

Expression of messenger RNA for amphiregulin, heregulin, and cripto-1, three new members of the epidermal growth factor family, in human breast carcinomas

scientific article published on 01 September 1995

External beam radiotherapy in bone metastatic prostate cancer: impact on patients' pain relief and quality of life.

artículo científico publicado en 2003

FCGR polymorphisms and cetuximab efficacy in chemorefractory metastatic colorectal cancer: an international consortium study.

artículo científico publicado en 2014

FOLFOX4 plus cetuximab treatment and RAS mutations in colorectal cancer.

artículo científico publicado en 2015

Factorial phase III randomised trial of rofecoxib and prolonged constant infusion of gemcitabine in advanced non-small-cell lung cancer: the GEmcitabine-COxib in NSCLC (GECO) study

artículo científico publicado en 2007

First-line erlotinib followed by second-line cisplatin-gemcitabine chemotherapy in advanced non-small-cell lung cancer: the TORCH randomized trial

artículo científico publicado en 2012

Fluorouracil, leucovorin, and irinotecan plus cetuximab treatment and RAS mutations in colorectal cancer

artículo científico publicado en 2015

Genetic Landscape of Primary Versus Metastatic Colorectal Cancer: to What Extent Are They Concordant?

Genomic Profiling of KRAS/NRAS/BRAF/PIK3CA Wild-Type Metastatic Colorectal Cancer Patients Reveals Novel Mutations in Genes Potentially Associated with Resistance to Anti-EGFR Agents

scientific article published on 20 June 2019

Global cancer control: responding to the growing burden, rising costs and inequalities in access.

artículo científico publicado en 2018

Growth of cells on a perfluorocarbon-medium interphase: A quantitative assay for anchorage-independent cell growth

artículo científico publicado en 1988

Guideline on the requirements of external quality assessment programs in molecular pathology.

artículo científico publicado en 2012

Gut microbiota correlates with antitumor activity in patients with <scp>mCRC</scp> and <scp>NSCLC</scp> treated with cetuximab plus avelumab

artículo científico publicado en 2022

HER2 signaling and resistance to the anti-EGFR monoclonal antibody cetuximab: a further step toward personalized medicine for patients with colorectal cancer.

artículo científico publicado en 2011

HGF/MET and the Immune System: Relevance for Cancer Immunotherapy ⬇️

journal article from 'International Journal of Molecular Sciences' published in 2018

Helicobacter pylori VacA toxin up-regulates vascular endothelial growth factor expression in MKN 28 gastric cells through an epidermal growth factor receptor-, cyclooxygenase-2-dependent mechanism.

artículo científico publicado en 2003

Hepatoid carcinoma colliding with a liposarcoma of the left colon serosa presenting as an abdominal mass.

artículo científico publicado en 2007

Heterogeneity of KRAS, NRAS, BRAF and PIK3CA mutations in metastatic colorectal cancer and potential effects on therapy in the CAPRI GOIM trial.

artículo científico publicado en 2015

High-dose recombinant interleukin-2/verapamil combination in advanced cancer

artículo científico publicado en 1996

Human epidermal growth factor receptor 2 (HER2) in gastric cancer: a new therapeutic target.

artículo científico publicado en 2010

ICECREAM: randomised phase II study of cetuximab alone or in combination with irinotecan in patients with metastatic colorectal cancer with either KRAS, NRAS, BRAF and PI3KCA wild type, or G13D mutated tumours

artículo científico publicado en 2016

Implication of the insulin-like growth factor-IR pathway in the resistance of non-small cell lung cancer cells to treatment with gefitinib

artículo científico publicado en 2007

Implications for KRAS status and EGFR-targeted therapies in metastatic CRC.

artículo científico publicado en 2009

Implications of KRAS mutation status for the treatment of metastatic colorectal cancer

artículo científico publicado en 2009

Improving outcomes in colorectal cancer: where do we go from here?

artículo científico

In vitro expansion of human breast cancer epithelial and mesenchymal stromal cells: optimization of a coculture model for personalized therapy approaches.

artículo científico publicado en 2007

Increased TGF-α as a mechanism of acquired resistance to the anti-EGFR inhibitor cetuximab through EGFR-MET interaction and activation of MET signaling in colon cancer cells

artículo científico publicado en 2013

Increased circulating levels of vascular endothelial growth factor C can predict outcome in resectable gastric cancer patients

Inhibition of Hedgehog signalling by NVP-LDE225 (Erismodegib) interferes with growth and invasion of human renal cell carcinoma cells

artículo científico publicado en 2014

Inhibition of bcl-2 as cancer therapy

artículo científico publicado en 2002

Interference with EGFR signaling: paradigm for improving radiation response in cancer treatment

artículo científico publicado en 2002

International Experts Panel Meeting of the Italian Association of Thoracic Oncology on Antiangiogenetic Drugs for Non-Small Cell Lung Cancer: Realities and Hopes

artículo científico publicado en 2016

Intrapatient cetuximab dose escalation in metastatic colorectal cancer according to the grade of early skin reactions: the randomized EVEREST study

artículo científico publicado en 2012

Intrinsic and acquired resistance to EGFR inhibitors in human cancer therapy.

artículo científico publicado en 2005

Investigation of two dosing schedules of vandetanib (ZD6474), an inhibitor of vascular endothelial growth factor receptor and epidermal growth factor receptor signaling, in combination with irinotecan in a human colon cancer xenograft model.

artículo científico publicado en 2007

Involvement of growth factor receptors of the epidermal growth factor receptor family in prostate cancer development and progression to androgen independence

artículo científico publicado en 2003

KRAS mutations testing in colorectal carcinoma patients in Italy: from guidelines to external quality assessment

artículo científico publicado en 2011

KRAS, BRAF, PIK3CA, and PTEN mutations: implications for targeted therapies in metastatic colorectal cancer.

artículo científico publicado en 2011

Key cancer cell signal transduction pathways as therapeutic targets.

artículo científico publicado en 2006

Kisspeptin and Cancer: Molecular Interaction, Biological Functions, and Future Perspectives.

artículo científico publicado en 2018

Limits and potential of targeted sequencing analysis of liquid biopsy in patients with lung and colon carcinoma.

scientific article published on 19 July 2016

Lymphomatoid papulosis

scientific article published on 20 January 2020

Maintenance treatment of advanced non-small-cell lung cancer: results of an international expert panel meeting of the Italian association of thoracic oncology

artículo científico publicado en 2012

Mechanisms of Intrinsic and Acquired Resistance to EGFR Inhibitors

Mechanisms of resistance to EGFR inhibitors

Mechanisms of resistance to EGFR-targeted drugs: lung cancer

artículo científico publicado en 2016

Medical treatment of small cell lung cancer: state of the art and new development

artículo científico

Metabolomic approach for a rapid identification of natural products with cytotoxic activity against human colorectal cancer cells.

artículo científico publicado en 2018

Metformin in lung cancer: rationale for a combination therapy

artículo científico publicado en 2013

Metformin increases antitumor activity of MEK inhibitors through GLI1 downregulation in LKB1 positive human NSCLC cancer cells

artículo científico publicado en 2015

Molecular aspects of resistance to biological and non-biological drugs and strategies to overcome resistance in colorectal cancer.

artículo científico publicado en 2014

Molecular markers and biological targeted therapies in metastatic colorectal cancer: expert opinion and recommendations derived from the 11th ESMO/World Congress on Gastrointestinal Cancer, Barcelona, 2009.

artículo científico publicado en 2010

Molecularly targeted therapies for colorectal cancer: Strategies for implementing translational research in clinical trials.

scientific article published on December 2010

NAB-paclitaxel and gemcitabine in metastatic pancreatic ductal adenocarcinoma (PDAC): from clinical trials to clinical practice.

artículo científico publicado en 2016

Neutrophil to lymphocyte ratio (NLR) for prediction of distant metastasis-free survival (DMFS) in early breast cancer: a propensity score-matched analysis.

artículo científico publicado en 2016

New insights on personalized cancer treatments: a report from the ESMO Congress

article

Novel In Vitro Cancer Models for Optimizing Anti-EGFR Therapies

artículo científico publicado en 2017

Novel investigational drugs for gastric cancer

artículo científico publicado en 2009

Novel toll-like receptor 9 agonist induces epidermal growth factor receptor (EGFR) inhibition and synergistic antitumor activity with EGFR inhibitors.

artículo científico publicado en 2006

Optimal treatment strategy for metastatic melanoma patients harboring BRAF-V600 mutations

artículo científico publicado en 2020

Optimising translational oncology in clinical practice: strategies to accelerate progress in drug development.

artículo científico

Optimization of the Development of Old and New EGFR and MAP Kinase Inhibitors for Colorectal Cancer

article

Optimizing Anti-EGFR Therapy in Colorectal Cancer.

artículo científico publicado en 2015

Optimizing treatment of metastatic colorectal cancer patients with anti-EGFR antibodies: overcoming the mechanisms of cancer cell resistance.

artículo científico publicado en 2013

Overcoming resistance to molecularly targeted anticancer therapies: Rational drug combinations based on EGFR and MAPK inhibition for solid tumours and haematologic malignancies ⬇️

artículo científico publicado en 2007

Panitumumab: the evidence of its therapeutic potential in metastatic colorectal cancer care.

artículo científico publicado en 2007

Pegylated liposomal doxorubicin: pharmacologic and clinical evidence of potent antitumor activity with reduced anthracycline-induced cardiotoxicity (review).

artículo científico publicado en 2004

Perioperative Treatment in Resectable Gastric Cancer: Current Perspectives and Future Directions

Perspectives in adjuvant therapy of gastric cancer.

artículo científico publicado en 2009

Pharmacogenomic and pharmacoproteomic studies of cetuximab in metastatic colorectal cancer: biomarker analysis of a phase I dose-escalation study.

artículo científico publicado en 2010

Phase I study of FOLFIRI plus pimasertib as second-line treatment for KRAS-mutated metastatic colorectal cancer

artículo científico publicado en 2015

Phase II Study of Preoperative Treatment with External Radiotherapy Plus Panitumumab in Low-Risk, Locally Advanced Rectal Cancer (RaP Study/STAR-03)

Phase II randomized study of vandetanib plus gemcitabine or gemcitabine plus placebo as first-line treatment of advanced non-small-cell lung cancer in elderly patients.

artículo científico publicado en 2014

Phase II study of gefitinib in combination with docetaxel as first-line therapy in metastatic breast cancer

artículo científico publicado en 2006

Phase II trial of cetuximab in combination with fluorouracil, leucovorin, and oxaliplatin in the first-line treatment of metastatic colorectal cancer

artículo científico publicado en 2007

Post-gemcitabine therapy for patients with advanced pancreatic cancer - A comparative review of randomized trials evaluating oxaliplatin- and/or irinotecan-containing regimens

artículo científico publicado en 2016

Potential Treatment Options After First-Line Chemotherapy for Advanced NSCLC: Maintenance Treatment or Early Second-Line?

artículo científico publicado en 2009

Potential role of molecularly targeted therapy in the management of advanced nonsmall cell lung carcinoma in the elderly

artículo científico publicado en 2004

Preclinical activity of the rational combination of selumetinib (AZD6244) in combination with vorinostat in KRAS-mutant colorectal cancer models.

scientific article published on 15 December 2011

Preclinical and phase I study of oxaliplatin and topotecan in combination in human cancer.

artículo científico publicado en 2002

Predictive value of epidermal growth factor receptor expression for first-line chemotherapy plus cetuximab in patients with head and neck and colorectal cancer: analysis of data from the EXTREME and CRYSTAL studies

artículo científico publicado en 2013

Primary and Acquired Resistance of Colorectal Cancer to Anti-EGFR Monoclonal Antibody Can Be Overcome by Combined Treatment of Regorafenib with Cetuximab.

artículo científico publicado en 2015

Primary and acquired resistance to anti-EGFR targeted drugs in cancer therapy

artículo científico publicado en 2007

Prognostic Significance of Epidermal Growth Factor Receptor Expression in Colon Cancer Patients Undergoing Curative Surgery

artículo científico publicado en 2006

Prognostic and Predictive Relevance of Primary Tumor Location in Patients With RAS Wild-Type Metastatic Colorectal Cancer: Retrospective Analyses of the CRYSTAL and FIRE-3 Trials

artículo científico

Prospective Study of Gefitinib in Epidermal Growth Factor Receptor Fluorescence In Situ Hybridization–Positive/Phospho-Akt–Positive or Never Smoker Patients With Advanced Non–Small-Cell Lung Cancer: The ONCOBELL Trial

artículo científico publicado en 2007

Protein kinase A as target for novel integrated strategies of cancer therapy.

artículo científico publicado en 2002

Protein kinase A type I: a target for cancer therapy

Pulmonary Large-Cell Neuroendocrine Carcinoma: From Epidemiology to Therapy.

artículo científico publicado en 2015

Quality of life analysis of TORCH, a randomized trial testing first-line erlotinib followed by second-line cisplatin/gemcitabine chemotherapy in advanced non-small-cell lung cancer

artículo científico publicado en 2012

Quality to rely on: meeting report of the 5th Meeting of External Quality Assessment, Naples 2016.

artículo científico publicado en 2016

Rational bases for the development of EGFR inhibitors for cancer treatment.

artículo científico publicado en 2007

Rational combination of targeted therapies as a strategy to overcome the mechanisms of resistance to inhibitors of EGFR signaling

scientific article published on January 2007

Rationale and design of MILES-3 and MILES-4 studies: two randomized phase 3 trials comparing single-agent chemotherapy versus cisplatin-based doublets in elderly patients with advanced non--small-cell lung cancer

artículo científico publicado en 2013

Re: Biomarkers predicting clinical outcome of epidermal growth factor receptor-targeted therapy in metastatic colorectal cancer

artículo científico publicado en 2010

Regorafenib plus modified FOLFOX6 as first-line treatment of metastatic colorectal cancer: A phase II trial.

artículo científico publicado en 2015

Regorafenib-associated hand-foot skin reaction: practical advice on diagnosis, prevention, and management.

artículo científico publicado en 2015

Reply to M.J. Rother

Reply to S. Debska-Szmich et al.

artículo científico publicado en 2015

Reply to V. Lorusso et al

artículo científico publicado en 2013

Reply to the letter to the editor 'Still a long way to go to achieve multidisciplinarity for the benefit of patients: commentary on the ESMO position paper' by Valentini et al

article

Resistance to Crizotinib in Advanced Non-Small Cell Lung Cancer (NSCLC) with ALK Rearrangement: Mechanisms, Treatment Strategies and New Targeted Therapies

artículo científico publicado en 2016

Response to Cetuximab With or Without Irinotecan in Patients With Refractory Metastatic Colorectal Cancer Harboring the KRAS G13D Mutation: Australasian Gastro-Intestinal Trials Group ICECREAM Study

artículo científico publicado en 2016

Role and targeting of anaplastic lymphoma kinase in cancer

artículo científico publicado en 2018

Role of HGF-MET Signaling in Primary and Acquired Resistance to Targeted Therapies in Cancer.

artículo científico publicado en 2014

Role of the cripto (EGF-CFC) family in embryogenesis and cancer.

artículo científico publicado en 2004

SMO Gene Amplification and Activation of the Hedgehog Pathway as Novel Mechanisms of Resistance to Anti-Epidermal Growth Factor Receptor Drugs in Human Lung Cancer.

artículo científico publicado en 2015

Safety and efficacy of sorafenib in patients with advanced hepatocellular carcinoma and Child-Pugh A or B cirrhosis

artículo científico publicado en 2015

Second-Line Treatment Options in Non-Small-Cell Lung Cancer: Report From an International Experts Panel Meeting of the Italian Association of Thoracic Oncology

artículo científico publicado en 2017

Second-line treatment of advanced non-small cell lung cancer

artículo científico publicado en 2008

Sequence-dependent antiproliferative effects of cytotoxic drugs and epidermal growth factor receptor inhibitors.

artículo científico publicado en 2005

Sequence-dependent inhibition of human colon cancer cell growth and of prosurvival pathways by oxaliplatin in combination with ZD6474 (Zactima), an inhibitor of VEGFR and EGFR tyrosine kinases

artículo científico publicado en 2006

Sequence-dependent, synergistic antiproliferative and proapoptotic effects of the combination of cytotoxic drugs and enzastaurin, a protein kinase Cbeta inhibitor, in non-small cell lung cancer cells.

artículo científico publicado en 2008

Serum insulin-like growth factor 1 correlates with the risk of nodal metastasis in endocrine-positive breast cancer

artículo científico publicado en 2013

Serum vascular endothelial growth factor (VEGF) levels correlate with tumor VEGF and p53 overexpression in endocrine positive primary breast cancer

artículo científico publicado en 2008

Shortening adjuvant chemotherapy in stage III colon cancer: are we ready for a change?

artículo científico publicado en 2018

Simultaneous blockage of different EGF-like growth factors results in efficient growth inhibition of human colon carcinoma xenografts.

artículo científico publicado en 2000

Small Molecule Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors in Non Small Cell Lung Cancer Treatment

Small molecule epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in non-small cell lung cancer.

artículo científico publicado en 2006

Sorafenib in combination with erlotinib or with gemcitabine in elderly patients with advanced non-small-cell lung cancer: a randomized phase II study.

artículo científico publicado en 2011

Spectroscopic Characterization and Cytotoxicity Assessment towards Human Colon Cancer Cell Lines of Acylated Cycloartane Glycosides from Astragalus boeticus L

scientific article published on 03 May 2019

Symptomatic toxicities experienced during anticancer treatment: agreement between patient and physician reporting in three randomized trials

artículo científico publicado en 2015

Synergistic anti-proliferative and pro-apoptotic activity of combined therapy with bortezomib, a proteasome inhibitor, with anti-epidermal growth factor receptor (EGFR) drugs in human cancer cells

artículo científico publicado en 2008

Synergistic anti-proliferative and pro-apoptotic activity of combined therapy with bortezomib, a proteasome inhibitor, with anti-epidermal growth factor receptor (EGFR) drugs in human cancer cells

Synergistic antitumor activity of ZD6474, an inhibitor of vascular endothelial growth factor receptor and epidermal growth factor receptor signaling, with gemcitabine and ionizing radiation against pancreatic cancer.

artículo científico publicado en 2006

Synergistic antitumor activity of sorafenib in combination with epidermal growth factor receptor inhibitors in colorectal and lung cancer cells

artículo científico publicado en 2010

Synergistic effects of metformin treatment in combination with gefitinib, a selective EGFR tyrosine kinase inhibitor, in LKB1 wild-type NSCLC cell lines.

artículo científico publicado en 2013

Synergistic inhibition of human cancer cell growth by cytotoxic drugs and mixed backbone antisense oligonucleotide targeting protein kinase A.

artículo científico publicado en 1997

TLR9 agonist acts by different mechanisms synergizing with bevacizumab in sensitive and cetuximab-resistant colon cancer xenografts

artículo científico publicado en 2007

Targeted approach to metastatic colorectal cancer: what comes beyond epidermal growth factor receptor antibodies and bevacizumab?

artículo científico

Targeting EGFR in pancreatic cancer treatment.

artículo científico publicado en 2012

Targeting of epidermal growth factor receptor and protein kinase A: molecular basis and therapeutic applications

artículo científico publicado en 2000

Targeting vascular endothelial growth factor receptor-1 and -3 with cediranib (AZD2171): effects on migration and invasion of gastrointestinal cancer cell lines

artículo científico publicado en 2009

The Cancer Moonshot from a European perspective

artículo científico publicado en 2017

The S492R EGFR ectodomain mutation is never detected in KRAS wild-type colorectal carcinoma before exposure to EGFR monoclonal antibodies

scientific article published on 23 September 2013

The c-Met inhibitors: a new class of drugs in the battle against advanced nonsmall-cell lung cancer

artículo científico

The current and future role of the medical oncologist in the professional care for cancer patients: a position paper by the European Society for Medical Oncology (ESMO).

artículo científico

The effects of cetuximab alone and in combination with radiation and/or chemotherapy in lung cancer.

artículo científico publicado en 2005

The liquid biopsy in the management of colorectal cancer patients: Current applications and future scenarios

artículo científico publicado en 2018

The potential role of bevacizumab in early stages and locally advanced non-small cell lung cancer

artículo científico publicado en 2009

The potential role of pharmacogenomic and genomic in the adjuvant treatment of early stage non small cell lung cancer ⬇️

scientific article published on June 2008

The rational basis of using novel targeted biological agents in non-small cell lung cancer.

artículo científico publicado en 2002

The role of EGFR inhibitors in nonsmall cell lung cancer

artículo científico publicado en 2004

The role of amphiregulin in breast cancer.

artículo científico publicado en 1995

The role of antiangiogenetic agents in the treatment of breast cancer.

artículo científico

The search for optimal response prediction in cancer leads to a personalized approach

scientific article published on 28 March 2010

The subgroups of the phase III RECOURSE trial of trifluridine/tipiracil (TAS-102) versus placebo with best supportive care in patients with metastatic colorectal cancer

artículo científico publicado en 2017

The tyrosine kinase inhibitor ZD6474 blocks proliferation of RET mutant medullary thyroid carcinoma cells.

artículo científico publicado en 2010

The use of xenograft models for the selection of cancer treatments with the EGFR as an example.

artículo científico publicado en 2008

Therapeutic efficacy of SYM004, a mixture of two anti-EGFR antibodies in human colorectal cancer with acquired resistance to cetuximab and MET activation

artículo científico publicado en 2017

Therapeutic value of EGFR inhibition in CRC and NSCLC: 15 years of clinical evidence

artículo científico publicado en 2016

Transformation of mouse mammary epithelial cells with the Ha-ras but not with the neu oncogene results in a gene dosage-dependent increase in transforming growth factor-alpha production.

artículo científico publicado en 1989

Transforming growth factor-alpha messenger RNA localization in the developing adult rat and human mammary gland by in situ hybridization.

artículo científico publicado en 1990

Transforming growth factors in human breast cancer

artículo científico publicado en 1989

Trastuzumab Resistance in Breast Cancer

Treatment decision-making for advanced non-small cell lung cancer and differences among European countries: 1st AIOT-ETOP meeting

artículo científico publicado en 2011

Treatment of Elderly Patients With Non-Small-Cell Lung Cancer: Results of an International Expert Panel Meeting of the Italian Association of Thoracic Oncology

artículo científico

Treatment of advanced non-small-cell lung cancer with epidermal growth factor receptor (EGFR) mutation or ALK gene rearrangement: results of an international expert panel meeting of the Italian Association of Thoracic Oncology

artículo científico publicado en 2013

Treatment of esophagogastric junction carcinoma: an unsolved debate

artículo científico publicado en 2015

Treatment of gastric cancer

artículo científico publicado en 2014

Treatment of locally advanced non-small cell lung cancer in the elderly.

artículo científico publicado en 2005

Trying to compose the puzzle with all the pieces: epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer

artículo científico publicado en 2005

Type III or allosteric kinase inhibitors for the treatment of non-small cell lung cancer

artículo científico

Understanding the mechanisms of action of EGFR inhibitors in NSCLC: what we know and what we do not know

artículo científico publicado en 2003

Unhealthy diets: a common soil for the association of metabolic syndrome and cancer

artículo científico publicado en 2014

Upregulated stromal EGFR and vascular remodeling in mouse xenograft models of angiogenesis inhibitor-resistant human lung adenocarcinoma

artículo científico publicado en 2011

Uptake of KRAS mutation testing in patients with metastatic colorectal cancer in Europe, Latin America and Asia

artículo científico publicado en 2011

Vandetanib, A Dual Inhibitor of VEGFR and EGFR Tyrosine Kinase Activity

Vascular endothelial growth factor and neo-angiogenesis inH. pylori gastritis in humans

artículo científico publicado en 2005

Vascular endothelial growth factor in pleural fluid for differential diagnosis of benign and malignant origin and its clinical applications

artículo científico publicado en 2010

Vascular endothelial growth factor receptor-1 contributes to resistance to anti-epidermal growth factor receptor drugs in human cancer cells.

artículo científico publicado en 2008

Weekly chemotherapy with cisplatin and paclitaxel and concurrent radiation therapy as preoperative treatment in locally advanced esophageal cancer: a phase II study.

artículo científico publicado en 2010

Weekly docetaxel and capecitabine is not effective in the treatment of advanced gastric cancer: a phase II study

artículo científico publicado en 2006

What's New in Gastric Cancer: The Therapeutic Implications of Molecular Classifications and Future Perspectives

artículo científico publicado en 2018

ZD1839 (IRESSA), an EGFR-selective tyrosine kinase inhibitor, enhances taxane activity in bcl-2 overexpressing, multidrug-resistant MCF-7 ADR human breast cancer cells

artículo científico publicado en 2002

ZD1839 (Iressa): preclinical studies and pharmacology

artículo científico publicado en 2002

ZD6474, an inhibitor of VEGFR and EGFR tyrosine kinase activity in combination with radiotherapy

artículo científico publicado en 2006

ZD6474, an orally available inhibitor of KDR tyrosine kinase activity, efficiently blocks oncogenic RET kinases.

artículo científico publicado en 2002

Zoledronic acid cooperates with a cyclooxygenase-2 inhibitor and gefitinib in inhibiting breast and prostate cancer.

artículo científico publicado en 2005

[EGF receptor blockade with monoclonal antibodis and so-called "small molecules"].

artículo científico publicado en 2005

[Rationales for the integration of molecular and conventional therapies]

artículo científico publicado en 2002

p27 downregulation and metallothionein overexpression in gastric cancer patients are associated with a poor survival rate

artículo científico publicado en 2006

Dominio Público Uruguay está sostenido por:

Acerca de Dominio Público Uruguay

Ayuda